# Polymeric Micellar Paclitaxel for Metastatic Pancreatic Cancer

> **NCT06752811** · PHASE3 · RECRUITING · sponsor: **Shanghai Yizhong Pharmaceutical Co., Ltd.** · enrollment: 416 (estimated)

## Conditions studied

- Pancreatic Cancer Metastatic

## Interventions

- **DRUG:** paclitaxel polymeric micelles for injection
- **DRUG:** Gemcitabine Hydrochloride for Injection
- **DRUG:** Paclitaxel for Injection (albumin bound )
- **DRUG:** Gemcitabine Hydrochloride for Injection

## Key facts

- **NCT ID:** NCT06752811
- **Lead sponsor:** Shanghai Yizhong Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-05
- **Primary completion:** 2027-07-01
- **Final completion:** 2027-12-31
- **Target enrollment:** 416 (ESTIMATED)
- **Last updated:** 2026-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06752811

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06752811, "Polymeric Micellar Paclitaxel for Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06752811. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*